NO20030374L - Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter - Google Patents

Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter

Info

Publication number: NO20030374L
Authority: NO; Norway
Prior art keywords: cyclopentanoindoles; compounds; treatment methods; preparations containing; treatment
Prior art date: 2000-07-25

Application number

NO20030374A

Other languages

English (en)

Other versions

NO20030374D0 (no

NO325011B1 (no

Inventor

Marc Labelle

Claudio Sturino

Bruno Roy

Carl Berthelette

Michael Boyd

Nicolas Lachance

John Scheigetz

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-25

Filing date

2003-01-24

Publication date

2003-01-24

2003-01-24 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

2003-01-24 Publication of NO20030374D0 publication Critical patent/NO20030374D0/no

2003-01-24 Publication of NO20030374L publication Critical patent/NO20030374L/no

2008-01-14 Publication of NO325011B1 publication Critical patent/NO325011B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/38—TPC being performed in particular situations
- H04W52/46—TPC being performed in particular situations in multi-hop networks, e.g. wireless relay networks
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04B—TRANSMISSION
- H04B17/00—Monitoring; Testing
- H04B17/30—Monitoring; Testing of propagation channels
- H04B17/309—Measuring or estimating channel quality parameters
- H04B17/318—Received signal strength
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/02—Access restriction performed under specific conditions
- H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/06—TPC algorithms
- H04W52/14—Separate analysis of uplink or downlink
- H04W52/146—Uplink power control
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission
- H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission taking into account the usage mode, e.g. hands-free, data transmission or telephone
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/20—Selecting an access point
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Signal Processing (AREA)
Computer Networks & Wireless Communication (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pulmonology (AREA)
Quality & Reliability (AREA)
Electromagnetism (AREA)
Physics & Mathematics (AREA)
Computer Security & Cryptography (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Steroid Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Materials For Photolithography (AREA)

NO20030374A 2000-07-25 2003-01-24 Syklopentanoindoler, preparater som inneholder slike forbindelser og anvendelse derav for fremstilling av medikamenter NO325011B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22068300P	2000-07-25	2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en)	2000-07-25	2001-07-23	Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (3)

Publication Number	Publication Date
NO20030374D0 NO20030374D0 (no)	2003-01-24
NO20030374L true NO20030374L (no)	2003-01-24
NO325011B1 NO325011B1 (no)	2008-01-14

Family

ID=22824535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20030374A NO325011B1 (no)	2000-07-25	2003-01-24	Syklopentanoindoler, preparater som inneholder slike forbindelser og anvendelse derav for fremstilling av medikamenter

Country Status (33)

Country	Link
US (1)	US6410583B1 (no)
EP (1)	EP1305286B1 (no)
JP (1)	JP4119745B2 (no)
KR (1)	KR100746814B1 (no)
CN (1)	CN1214007C (no)
AT (1)	ATE284388T1 (no)
AU (2)	AU2001277430B2 (no)
BG (1)	BG66084B1 (no)
BR (1)	BR0112756A (no)
CA (1)	CA2416867C (no)
CZ (1)	CZ2003236A3 (no)
DE (1)	DE60107687T2 (no)
DK (1)	DK1305286T3 (no)
DZ (1)	DZ3402A1 (no)
EA (1)	EA006765B1 (no)
EC (1)	ECSP034428A (no)
EE (1)	EE05287B1 (no)
ES (1)	ES2231526T3 (no)
GE (1)	GEP20053595B (no)
HR (1)	HRP20021039B1 (no)
HU (1)	HUP0301745A3 (no)
IL (2)	IL153406A0 (no)
IS (1)	IS2170B (no)
MX (1)	MXPA03000710A (no)
NO (1)	NO325011B1 (no)
NZ (1)	NZ523106A (no)
PL (1)	PL207342B1 (no)
PT (1)	PT1305286E (no)
RS (1)	RS50491B (no)
SK (1)	SK287507B6 (no)
UA (1)	UA73787C2 (no)
WO (1)	WO2002008186A2 (no)
ZA (1)	ZA200300554B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
AU759641B2 (en)	1998-08-19	2003-04-17	Skyepharma Canada Inc.	Injectable aqueous dispersions of propofol
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
AU2002239463A1 (en) *	2000-11-03	2002-06-03	Wyeth	Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
AR031196A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
US6777407B2 (en)	2000-11-03	2004-08-17	Wyeth	Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6858604B2 (en)	2000-11-03	2005-02-22	Wyeth	Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6916922B2 (en)	2000-11-03	2005-07-12	Wyeth	Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
US6759405B2 (en)	2000-11-03	2004-07-06	Wyeth	Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031197A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TWI312781B (en)	2002-04-25	2009-08-01		[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en)	2002-04-25	2003-12-16	Wyeth Corp	[1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en)	2002-04-25	2003-12-16	Wyeth Corp	1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400818A (en)	2002-05-21	2004-01-16	Wyeth Corp	Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en)	2002-05-21	2004-01-16	Wyeth Corp	R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
EP1631547A1 (en) *	2003-05-20	2006-03-08	Merck Frosst Canada Ltd.	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
WO2004111047A2 (en) *	2003-06-12	2004-12-23	Merck Frosst Canada Ltd.	Cycloalkanepyrrolopyridines as dp receptor antagonists
WO2005013985A1 (en) *	2003-08-07	2005-02-17	Merck Sharp & Dohme Limited	Treatment for alzheimer's disease and related conditions
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
KR20070033032A (ko)	2004-07-16	2007-03-23	프로테오시스 악티엔게젤샤프트	세포보호제로서 ｐａｒｐ 및 ｓｉｒ 조절 활성을 갖는무스카린 길항제
HN2005000795A (es)	2004-10-15	2010-08-19	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es)	2004-11-05	2006-10-27		Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1874301A4 (en) *	2005-04-13	2009-05-06	Merck & Co Inc	Niacin receptor agonists, compositions containing such compounds and treatment methods
US7902177B2 (en)	2005-05-02	2011-03-08	Wandzel Richard A	Treatment of congestion using steroids and adrenergics
AR054849A1 (es)	2005-07-26	2007-07-18	Wyeth Corp	Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP2114154B1 (en) *	2007-02-08	2013-08-28	Merck Sharp & Dohme Corp.	Method of treating atherosclerosis, dyslipidemias and related conditions
EA019252B1 (ru) *	2008-07-23	2014-02-28	Арена Фармасьютикалз, Инк.	ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
PT2342205T (pt) *	2008-08-27	2016-07-28	Arena Pharm Inc	Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios
WO2010030360A1 (en)	2008-09-11	2010-03-18	Arena Pharmaceuticals, Inc.	3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
EP2346866B1 (en) *	2008-09-25	2013-11-27	Merck Canada Inc.	Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
EP2387405A2 (en)	2009-01-13	2011-11-23	ProteoSys AG	Pirenzepine as an agent in cancer treatment
JP2013508339A (ja)	2009-10-26	2013-03-07	バイエル・クロップサイエンス・アーゲー	４−［［（６−クロロピリジン−３−イル）メチル］（２，２−ジフルオロエチル）アミノ］フラン−２（５ｈ）−オンの新規固体形態
SG10201500639TA (en)	2010-01-27	2015-03-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
WO2014066568A1 (en)	2012-10-24	2014-05-01	Winthrop-University Hospital	Non-invasive biomarker to identify subjects at risk of preterm delivery
HUE069888T2 (hu)	2015-01-06	2025-04-28	Arena Pharm Inc	Vegyületek az S1P1 receptorral összefüggõ állapotok kezelésében történõ alkalmazásra
WO2016128565A1 (en) *	2015-02-13	2016-08-18	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
KR102883123B1 (ko)	2015-06-22	2025-11-10	아레나 파마슈티칼스, 인크.	Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
JP2020507610A (ja)	2017-02-16	2020-03-12	アリーナファーマシューティカルズ，インコーポレイテッド	腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
MA47504A (fr)	2017-02-16	2019-12-25	Arena Pharm Inc	Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN111094988A (zh)	2017-09-13	2020-05-01	普罗根尼蒂公司	先兆子痫生物标志物及相关系统和方法
US11279656B2 (en) *	2017-10-27	2022-03-22	Applied Materials, Inc.	Nanopowders, nanoceramic materials and methods of making and use thereof
CN112601516A (zh)	2018-06-06	2021-04-02	艾尼纳制药公司	治疗与s1p1受体相关的病况的方法
CN112955431A (zh)	2018-09-06	2021-06-11	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN115260173B (zh) *	2021-04-30	2024-08-30	厦门宝太生物科技股份有限公司	环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) *	2023-07-10	2023-10-10	青岛科技大学	一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr)	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en)	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en)	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
ATE61047T1 (de)	1986-01-23	1991-03-15	Merck Frosst Canada Inc	Tetrahydrocarbazol-1-alkansaeuren.
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
KR100428601B1 (ko) *	1995-06-21	2004-09-16	시오노기세이야쿠가부시키가이샤	비사이클릭아미노유도체및이들을함유하는프로스타글란딘디2길항제
IL130660A (en) *	1996-12-13	2002-03-10	Shionogi & Co	History of benzothiophenecarboxamide and PGD2 antibodies containing them
ES2241283T3 (es) *	1998-06-03	2005-10-16	SHIONOGI & CO., LTD.	Remedios para el tratamiento del prurito que contienen antagonistas de pgd2.

2001
- 2001-07-20 US US09/909,636 patent/US6410583B1/en not_active Expired - Lifetime
- 2001-07-23 GE GE5105A patent/GEP20053595B/en unknown
- 2001-07-23 HU HU0301745A patent/HUP0301745A3/hu unknown
- 2001-07-23 JP JP2002514093A patent/JP4119745B2/ja not_active Expired - Fee Related
- 2001-07-23 AU AU2001277430A patent/AU2001277430B2/en not_active Expired
- 2001-07-23 PT PT01955162T patent/PT1305286E/pt unknown
- 2001-07-23 IL IL15340601A patent/IL153406A0/xx active IP Right Grant
- 2001-07-23 EA EA200300171A patent/EA006765B1/ru not_active IP Right Cessation
- 2001-07-23 PL PL363168A patent/PL207342B1/pl not_active IP Right Cessation
- 2001-07-23 DZ DZ013402A patent/DZ3402A1/fr active
- 2001-07-23 DK DK01955162T patent/DK1305286T3/da active
- 2001-07-23 HR HR20021039A patent/HRP20021039B1/xx not_active IP Right Cessation
- 2001-07-23 CN CNB018131662A patent/CN1214007C/zh not_active Expired - Fee Related
- 2001-07-23 CA CA002416867A patent/CA2416867C/en not_active Expired - Fee Related
- 2001-07-23 ES ES01955162T patent/ES2231526T3/es not_active Expired - Lifetime
- 2001-07-23 UA UA2003021565A patent/UA73787C2/uk unknown
- 2001-07-23 MX MXPA03000710A patent/MXPA03000710A/es active IP Right Grant
- 2001-07-23 AU AU7743001A patent/AU7743001A/xx active Pending
- 2001-07-23 EP EP01955162A patent/EP1305286B1/en not_active Expired - Lifetime
- 2001-07-23 RS YUP-979/02A patent/RS50491B/sr unknown
- 2001-07-23 SK SK93-2003A patent/SK287507B6/sk not_active IP Right Cessation
- 2001-07-23 NZ NZ523106A patent/NZ523106A/en not_active IP Right Cessation
- 2001-07-23 BR BR0112756-0A patent/BR0112756A/pt active Search and Examination
- 2001-07-23 KR KR1020037001117A patent/KR100746814B1/ko not_active Expired - Lifetime
- 2001-07-23 AT AT01955162T patent/ATE284388T1/de active
- 2001-07-23 CZ CZ2003236A patent/CZ2003236A3/cs unknown
- 2001-07-23 DE DE60107687T patent/DE60107687T2/de not_active Expired - Lifetime
- 2001-07-23 EE EEP200300033A patent/EE05287B1/xx not_active IP Right Cessation
- 2001-07-23 WO PCT/CA2001/001069 patent/WO2002008186A2/en not_active Ceased
2002
- 2002-12-12 IS IS6655A patent/IS2170B/is unknown
- 2002-12-12 IL IL153406A patent/IL153406A/en not_active IP Right Cessation
2003
- 2003-01-06 BG BG107438A patent/BG66084B1/bg unknown
- 2003-01-13 EC EC2003004428A patent/ECSP034428A/es unknown
- 2003-01-21 ZA ZA200300554A patent/ZA200300554B/en unknown
- 2003-01-24 NO NO20030374A patent/NO325011B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ2003236A3 (cs)	2003-05-14
IL153406A0 (en)	2003-07-06
CA2416867A1 (en)	2002-01-31
NO20030374D0 (no)	2003-01-24
HRP20021039B1 (hr)	2011-03-31
SK932003A3 (en)	2003-06-03
DK1305286T3 (da)	2005-03-14
US6410583B1 (en)	2002-06-25
AU2001277430B2 (en)	2006-05-25
DE60107687T2 (de)	2005-12-01
EE200300033A (et)	2004-10-15
EE05287B1 (et)	2010-04-15
YU97902A (sh)	2006-05-25
KR100746814B1 (ko)	2007-08-06
UA73787C2 (en)	2005-09-15
JP2004504380A (ja)	2004-02-12
EA006765B1 (ru)	2006-04-28
ZA200300554B (en)	2004-04-23
RS50491B (sr)	2010-03-02
CN1443165A (zh)	2003-09-17
SK287507B6 (sk)	2010-12-07
DZ3402A1 (fr)	2002-01-31
EP1305286A2 (en)	2003-05-02
EP1305286B1 (en)	2004-12-08
IS2170B (is)	2006-11-15
KR20030024810A (ko)	2003-03-26
ES2231526T3 (es)	2005-05-16
MXPA03000710A (es)	2003-06-04
CA2416867C (en)	2008-03-25
NO325011B1 (no)	2008-01-14
WO2002008186A3 (en)	2002-03-21
BG107438A (bg)	2003-09-30
IL153406A (en)	2008-03-20
HUP0301745A2 (hu)	2003-09-29
IS6655A (is)	2002-12-12
PT1305286E (pt)	2005-04-29
DE60107687D1 (de)	2005-01-13
HK1058934A1 (en)	2004-06-11
HRP20021039A2 (en)	2004-10-31
PL363168A1 (en)	2004-11-15
GEP20053595B (en)	2005-08-10
HUP0301745A3 (en)	2010-03-29
EA200300171A1 (ru)	2003-06-26
BG66084B1 (bg)	2011-03-31
ECSP034428A (es)	2003-03-10
AU7743001A (en)	2002-02-05
BR0112756A (pt)	2003-06-24
PL207342B1 (pl)	2010-12-31
NZ523106A (en)	2005-01-28
CN1214007C (zh)	2005-08-10
WO2002008186A2 (en)	2002-01-31
JP4119745B2 (ja)	2008-07-16
ATE284388T1 (de)	2004-12-15

Publication	Publication Date	Title
NO20030374D0 (no)	2003-01-24	Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
JO2481B1 (en)	2009-01-20	Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
DK1206474T3 (da)	2004-10-04	Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DK1343782T3 (da)	2009-08-24	Pyrimidinaminer som angiogenesemodulatorer
NO20014986D0 (no)	2001-10-12	4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
CY1108067T1 (el)	2014-02-12	Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
DK1097173T3 (da)	2008-09-01	Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO20043016L (no)	2004-07-15	6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
EA200301142A1 (ru)	2004-02-26	Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE300541T1 (de)	2005-08-15	Pyrazolopyridinderivate
CY1105387T1 (el)	2010-04-28	Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
CY1105247T1 (el)	2010-03-03	Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
NO20050019L (no)	2005-02-23	Polytylenglykolaldehyd-derivater
CY1106376T1 (el)	2011-10-12	Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
NO20014241D0 (no)	2001-08-31	C16-umettede FP-selektive prostaglandinanaloger
ATE419242T1 (de)	2009-01-15	Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EA200300727A1 (ru)	2004-02-26	Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
TR200101693T2 (tr)	2002-06-21	Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
CY1106712T1 (el)	2012-05-23	Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
CY1105275T1 (el)	2010-03-03	Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
DK1177191T3 (da)	2004-04-05	Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
IT1289154B1 (it)	1998-09-29	Derivati di isoflavone loro preparazione e loro impiego terapeutico
CY1111290T1 (el)	2015-08-05	Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
SE9803277D0 (sv)	1998-09-25	Novel compounds

Legal Events

Date	Code	Title	Description
2013-09-09	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ACAPO AS, NO
2015-02-23	MM1K	Lapsed by not paying the annual fees